electroCore Quell Device Clinical Trial Shows Significant Improvement in Fibromyalgia Patients
electroCore published clinical findings in JAMA Network Open from a cluster randomized trial evaluating its Quell device added to outpatient physical therapy, or PT, in 384 fibromyalgia patients. At day 60, reduction in movement-evoked pain was significantly greater in the PT-Quell group compared with the PT-only group, with statistically significant improvements also seen in resting pain, pain interference, movement-evoked fatigue, resting fatigue, and fibromyalgia impact. Benefits were observed within 30 days and sustained for up to six months, with 81% of respondents finding Quell helpful and 55% continuing daily use.
